Raízen's $12.6 Billion Restructuring Is a Creditors' Rescue - Not a Shareholder Opportunity

Raízen's $12.6 billion debt restructuring deal isn't a turnaround story. It's a creditors' rescue operation that will almost certainly wipe out existing equity. The company announced the plan in March and has been sending creditor options ever since - but the math that matters isn't on the restructuring timeline. It's on the dilution math, the falling cash flow, and the fact that no owner is stepping in to save the balance sheet.

Let me start with the restructuring terms, because those are where the shareholder destruction hides in plain sight.

Raízen presented creditors with three options for its roughly R$65 billion ($12.6 billion) in unsecured debt. Option A converts 45% of the debt into equity at R$0.25 per share. Option B delivers an 80% haircut with a single cash payment due in March 2047. Option A is clearly the one Raízen wants - more debt gone from the balance sheet, replaced by equity that carries no interest payments. But here's the mechanism that matters for existing shareholders: at R$0.25 per share, converting even 45% of that R$65 billion debt means issuing roughly 117 billion new shares. Raízen currently has approximately 10.3 billion shares outstanding. Existing shareholders would be diluted to near-zero ownership. Even if you don't take the exact math literally - because the final terms aren't set - the direction is unmistakable. Equity is being used as currency to buy down debt, and at a price that treats existing shares as deeply distressed.

Creditors holding just 47% of the restructuring debt initially agreed to the plan, well short of the 50% threshold needed to bind holdouts. That's why Raízen has been in extended talks, sending revised proposals and trying to coax more support. Creditors have reportedly asked for up to 90% of the company's equity in exchange for accepting the debt-to-equity swap on just 45% of the total debt. If that pricing holds, post-restructuring equity will belong almost entirely to former creditors. Existing shareholders - Cosan (roughly 44% through direct and indirect holdings) and Shell Brazil (roughly 44%) - stand to be reduced to minority positions or worse.

The fact that Cosan and Shell were negotiating a capital injection to rescue Raízen, then let those talks collapse in early March, tells you something about how the owners view the economics. They walked away. That matters because capital injection talks collapsing signals that even the majority owners couldn't justify putting more money into a company whose balance sheet total liabilities approach R$120 billion - nearly 30 times its current market capitalization of approximately R$4 billion.

Now let's talk about the operating business, because a restructuring plan only matters if the underlying cash flow can service what's left of the debt.

Raízen's third quarter of the 2025-26 crop year showed a R$15.6 billion net loss, driven largely by a R$11.1 billion non-cash asset impairment. Adjusted EBITDA - earnings before interest, taxes, depreciation, and amortization, a rough proxy for operating cash generation - totaled R$3.15 billion for the quarter, down 3.3% year over year. But the more telling number is in the core Sugar, Ethanol and Bioenergy segment, where adjusted EBITDA fell 34% year over year to R$1.23 billion. Revenue declined 9.7% to R$60.4 billion.

This is a commodity-exposed business with no fee-based insulation. Sugar and ethanol prices swing with crop cycles, weather, and energy policy - not management decisions. The 34% collapse in the core segment's cash earnings tells you that when the commodity cycle turns, the cash flow turns with it. There's no pipeline-like fee structure absorbing the shock. The EBITDA margin has fallen below 5%, and management was targeting a return to 6% for fiscal 2026 - an aspirational goal that now looks detached from the restructuring reality.

Debt to EBITDA stood at 5.6 times as of September 2025, according to S&P's analysis. That number will mechanically improve after the restructuring because debt converts to equity. But improvement on paper doesn't create new cash flow. The post-restructuring leverage looks better only because the debt is gone - not because the business generates more cash.

Here's the contrarian question the headline doesn't ask: even if Raízen survives this restructuring, is there a reason to own the equity?

The answer is no. Value investing requires a margin of safety - a price that sits below intrinsic value with room for error. Raízen's equity at R$0.38 per share appears cheap only because it is trading through the floor. A stock that could be diluted to near-zero ownership doesn't have a margin of safety; it has an execution risk. The restructuring hasn't completed. Holdout creditors exist. Fitch already downgraded Raízen's domestic ratings to C and S&P put it at Selective Default. These aren't footnotes - they're the market's way of pricing in the possibility that the plan unravels or that creditors demand terms even more hostile to existing equity.

While it's true that Raízen operates in Brazil's biofuels sector, which has long-term structural tailwinds from ethanol blending mandates and the renewable energy transition, those tailwinds don't protect shareholders from dilution and balance-sheet stress. The tailwinds protect the business, not the equity.

Even if the restructuring succeeds and Raízen emerges with a cleaner balance sheet, existing shareholders would own such a fraction of the post-restructuring company that any recovery is functionally irrelevant. And if you're considering initiating a position now, the question is whether you can time entry before the new shares are issued at R$0.25 - which is itself a trading call, not a value investment.

All things considered, Raízen's restructuring is a textbook case of what happens when a commodity-exposed operator builds too much debt and runs into the wrong cycle. The creditors get the company. The business may survive. The existing equity doesn't. There are better opportunities elsewhere - in names where cash flow is predictable, leverage is manageable, and you're not sitting at the bottom of the capital structure when the next crisis hits.

I would rate Raízen a Sell for existing holders and a Pass for anyone looking at the headline cheapness. A bankrupt cheap stock is not a value investment. A diluted cheap stock is even worse.